ClinicalTrials.gg
CompletedNCT06935266Updated Aug 17, 2026Results posted

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

A Phase 1 interventional study of TAK-881 and SC Investigational Needle Sets in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules.

During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous [SC] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels.

Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment [EOT]).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and Women between 18 and 50 years can participate.
  2. Must be a non-smoker, with no use of nicotine or tobacco products for at least 3 months prior to the first dosing.
  3. Must have (BMI) between 18.0 and 30.0 kilograms per square meter (kg/m\^2).
  4. Must be medically healthy.
  5. Must follow protocol-specified guidance.

Exclusion criteria

Exclusion Criteria:

  1. Any current or past medical history of blood/clotting disorder, liver, lung, heart, kidney, immune, skin, or brain or psychiatric condition.
  2. History of alcohol or drug abuse within 2 years before dosing.
  3. History or presence of or severe allergic reactions to blood or blood components.
  4. History or presence of thrombotic/thromboembolic events, or venous thrombosis.
  5. Pregnant or breastfeeding.
  6. Unable to refrain from taking prescription and non-prescription medications, herbal remedies, homeopathic preparations, or vitamin supplements.
  7. Recently donated blood or blood products.
  8. Participated in another clinical trial involving immunoglobulin products within 12 months of screening.
  9. Has taken biologic agents within 12 weeks of screening.
  10. Has used an product within 30 days or 5 half-lives, whichever is longer, prior to screening.
  11. Has received any vaccine (including and coronavirus disease 2019 [COVID-19] vaccines) during the last 30 days before dosing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Cohort 1, Schedule B, Treatment Arm 1: TAK-881

    Participants will receive TAK-881, subcutaneous (SC) injection, 0.15 grams per kilogram (g/kg) on Day 1, 0.3 g/kg on Day 8, 0.6 g/kg on Days 22 and 50 in ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 1, Schedule C, Treatment Arm 2: TAK-881

    Participants will receive TAK-881, SC injection, 0.6 g/kg on Days 1, 29 and 57 in no ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 2, Schedule A, Treatment Arm 3: TAK-881

    Participants will receive TAK-881, SC injection, 0.25 g/kg on Days 1 and 8, 0.5 g/kg on Day 15, 0.75 g/kg on Day 29 and 1.0 g/kg on Day 50 in ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 2, Schedule B: Treatment Arm 4: TAK-881

    Participants will receive TAK-881, SC injection, 0.25 g/kg on Day 1, 0.5 g/kg on Day 8, 1.0 g/kg on Days 22 and 50 in ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 2, Schedule C: Treatment Arm 5: TAK-881

    Participants will receive TAK-881, SC injection, 1.0 g/kg on Days 1, 29 and 57 in no ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 3, Schedule A: Treatment Arm 6: TAK-881

    Participants will receive TAK-881, SC injection, 0.5 g/kg on Days 1 and 8, 1.0 g/kg on Day 15, 1.5 g/kg on Day 29 and 2.0 g/kg on Day 50 in ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 3, Schedule B: Treatment Arm 7: TAK-881

    Participants will receive TAK-881, SC injection, 0.5 g/kg on Day 1, 1.0 g/kg on Day 8, 2.0 g/kg on Days 22 and 50 in ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    Cohort 3, Schedule C: Treatment Arm 8: TAK-881

    Participants will receive TAK-881, SC injection, 2.0 g/kg, on Days 1, 29 and 57 in no ramp-up dosing manner.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

Interventions

  • BiologicalTAK-881

    TAK-881 SC injection.

    Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)

  • DeviceSC Investigational Needle Sets

    The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment

    A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any treatment-emergent adverse events (TEAEs) related to TAK-881. An infusion was considered to be tolerable if the participant had tolerated both the recombinant human hyaluronidase (rHuPH20) and immune globulin subcutaneous (IGSC) 20 percent (%) components of TAK-881. The number of participants who tolerated all initiated infusions by TAK-881 treatment were reported in this outcome measure.

    Time frame: Up to Day 57

  2. Number of Tolerable Infusions by TAK-881 Treatment

    A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any TEAEs related to TAK-881. The number of tolerable infusions by TAK-881 treatment were reported in this outcome measure.

    Time frame: Up to Day 57

Secondary outcomes

  1. Number of Participants With TEAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the investigational product (IP), whether or not the occurrence was considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the IP. A TEAE was defined as any AE that was not present prior to the initiation of the treatments or any pre-existing AE that worsened in either intensity or frequency after receiving the first dose of trial intervention in this trial through 98 (±7) days after the last dose of trial intervention. Number of participants with TEAEs were reported in this outcome measure.

    Time frame: From start of study drug administration up to end of trial (EOT) (up to Week 16)

  2. Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Clinical laboratory parameters included analysis of serum chemistry, hematology, coagulation and urinalysis. Clinical significance of laboratory values was determined at the investigator's discretion.

    Time frame: From start of study drug administration up to EOT (up to Week 16)

  3. Number of Participants With Clinically Significant Changes in Vital Sign Parameters

    Vital signs parameters included measurement of pulse rate, blood pressure, body temperature and respiratory rate. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: From start of study drug administration up to EOT (up to Week 16)

  4. Number of Participants With Positive Binding Antibodies to rHuPH20

    The binding antibodies were considered as "positive" if corresponding titer was \>= 1:160. Number of participants with positive binding antibodies to rHuPH20 with titer \>=1:160 were reported in this outcome measure.

    Time frame: Up to Week 16

  5. Number of Participants With Neutralizing Antibodies to Anti-rHuPH20

    All participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the screening and confirmatory binding assay). Post-dose samples with antibody titers \>=1 :160 were analyzed for the presence of neutralizing-ADA using a validated assay based on neutralization of rHuPH20 activity. Number of participants with neutralizing antibodies to anti-rHuPH20 were reported in this outcome measure.

    Time frame: Up to Week 16

07

Results

Posted Aug 17, 2026

Participant flow

Participants took part in the study at 1 investigative site in the United States from 22 April 2025 to 27 September 2025.

Participant flow — Overall Study
MilestoneCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Started88888888
Completed78688774
Not completed10200114
Withdrew: Non-compliance10100000
Withdrew: Adverse event00100011
Withdrew: Withdrawal by subject00000103

Outcome measures

PrimaryNumber of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment

A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any treatment-emergent adverse events (TEAEs) related to TAK-881. An infusion was considered to be tolerable if the participant had tolerated both the recombinant human hyaluronidase (rHuPH20) and immune globulin subcutaneous (IGSC) 20 percent (%) components of TAK-881. The number of participants who tolerated all initiated infusions by TAK-881 treatment were reported in this outcome measure.

Time frame:
Up to Day 57
Reported as:
Count of participants · Participants
Number of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment
ParticipantsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Number of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment8 (63 to 100)8 (63 to 100)8 (63 to 100)8 (63 to 100)8 (63 to 100)8 (63 to 100)8 (63 to 100)8 (63 to 100)
PrimaryNumber of Tolerable Infusions by TAK-881 Treatment

A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any TEAEs related to TAK-881. The number of tolerable infusions by TAK-881 treatment were reported in this outcome measure.

Time frame:
Up to Day 57
Reported as:
Number · number of infusions
Number of Tolerable Infusions by TAK-881 Treatment
number of infusionsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Number of Tolerable Infusions by TAK-881 Treatment31 (89 to 100)24 (86 to 100)35 (90 to 100)32 (89 to 100)24 (86 to 100)46 (92 to 100)42 (92 to 100)31 (89 to 100)
SecondaryNumber of Participants With TEAEs

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the investigational product (IP), whether or not the occurrence was considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the IP. A TEAE was defined as any AE that was not present prior to the initiation of the treatments or any pre-existing AE that worsened in either intensity or frequency after receiving the first dose of trial intervention in this trial through 98 (±7) days after the last dose of trial intervention. Number of participants with TEAEs were reported in this outcome measure.

Time frame:
From start of study drug administration up to end of trial (EOT) (up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs
ParticipantsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Number of Participants With TEAEs88888888
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Clinical laboratory parameters included analysis of serum chemistry, hematology, coagulation and urinalysis. Clinical significance of laboratory values was determined at the investigator's discretion.

Time frame:
From start of study drug administration up to EOT (up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Serum Chemistry00000011
Hematology00100111
Coagulation00000000
Urinalysis10000000
SecondaryNumber of Participants With Clinically Significant Changes in Vital Sign Parameters

Vital signs parameters included measurement of pulse rate, blood pressure, body temperature and respiratory rate. Clinical significance of vital signs was determined at the investigator's discretion.

Time frame:
From start of study drug administration up to EOT (up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
ParticipantsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Pulse Rate10000000
Blood Pressure00000000
Body Temperature00001000
Respiratory Rate00000000
SecondaryNumber of Participants With Positive Binding Antibodies to rHuPH20

The binding antibodies were considered as "positive" if corresponding titer was \>= 1:160. Number of participants with positive binding antibodies to rHuPH20 with titer \>=1:160 were reported in this outcome measure.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Positive Binding Antibodies to rHuPH20
ParticipantsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Number of Participants With Positive Binding Antibodies to rHuPH2000000100
SecondaryNumber of Participants With Neutralizing Antibodies to Anti-rHuPH20

All participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the screening and confirmatory binding assay). Post-dose samples with antibody titers \>=1 :160 were analyzed for the presence of neutralizing-ADA using a validated assay based on neutralization of rHuPH20 activity. Number of participants with neutralizing antibodies to anti-rHuPH20 were reported in this outcome measure.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies to Anti-rHuPH20
ParticipantsCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Participants with Positive Neutralizing Antibodies00000000
Participants with Negative Neutralizing Antibodies00000100

Adverse events

Collected over From start of study drug administration up to EOT (up to Week 16). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: TAK-881 Ramp-up Schedule B0/8 (0%)1/8 (12.5%)8/8 (100%)
Cohort 1: TAK-881 No Ramp-up Schedule C0/8 (0%)0/8 (0%)8/8 (100%)
Cohort 2: TAK-881 Ramp-up Schedule A0/8 (0%)0/8 (0%)8/8 (100%)
Cohort 2: TAK-881 Ramp-up Schedule B0/8 (0%)0/8 (0%)8/8 (100%)
Cohort 2: TAK-881 No Ramp-up Schedule C0/8 (0%)0/8 (0%)8/8 (100%)
Cohort 3: TAK-881 Ramp-up Schedule A0/8 (0%)0/8 (0%)8/8 (100%)
Cohort 3: TAK-881 Ramp-up Schedule B0/8 (0%)0/8 (0%)8/8 (100%)
Cohort 3: TAK-881 No Ramp-up Schedule C0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/80/80/80/80/80/80/80/8
Most frequent other events
Showing 10 of 72
Most frequent other events
EventCohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule C
Infusion site erythemaGeneral disorders8/88/88/88/88/88/87/88/8
Infusion site painGeneral disorders5/88/85/84/87/88/86/86/8
Infusion site swellingGeneral disorders8/88/88/88/88/88/88/88/8
HeadacheNervous system disorders1/83/84/85/84/85/86/87/8
Infusion site indurationGeneral disorders1/82/82/83/82/87/81/82/8
Infusion site pruritusGeneral disorders3/85/83/82/82/87/87/85/8
Infusion site warmthGeneral disorders1/81/80/85/82/86/82/83/8
DizzinessNervous system disorders0/81/80/80/80/80/83/80/8
Infusion site discomfortGeneral disorders0/83/80/80/80/82/81/82/8
Infusion site haemorrhageGeneral disorders0/80/80/81/82/83/80/80/8

Baseline characteristics

The safety analysis set (SAS) included all participants who received any amount of TAK-881.

Age, Categorical
Age, Categorical(Participants)Cohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule CTotal
<=18 years000000000
Between 18 and 65 years8888888864
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule CTotal
Female4874534237
Male4014354627
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule CTotal
Hispanic or Latino7788778860
Not Hispanic or Latino110011004
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: TAK-881 Ramp-up Schedule BCohort 1: TAK-881 No Ramp-up Schedule CCohort 2: TAK-881 Ramp-up Schedule ACohort 2: TAK-881 Ramp-up Schedule BCohort 2: TAK-881 No Ramp-up Schedule CCohort 3: TAK-881 Ramp-up Schedule ACohort 3: TAK-881 Ramp-up Schedule BCohort 3: TAK-881 No Ramp-up Schedule CTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American121020129
White7678686654
More than one race000000101
Unknown or Not Reported000000000
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Sep 2025, 5 months.

Results were first posted in Aug 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 20, 2025
StartActual
Apr 22, 2025
Primary completionActual
Sep 27, 2025
CompletionActual
Sep 27, 2025
Results first posted
Aug 17, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06935266
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
Apr 22, 2025
Primary completion
Sep 27, 2025
Completion
Sep 27, 2025
Results posted
Aug 17, 2026
Last update
Aug 17, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion